Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
The Science Business
Org Prep Daily
Kilomentor
On Pharma
Kinase Pro
Pharma Conduct
One in Ten Thousand
Periodic Tabloid
All Things Metathesis
C&E News Blog
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Chirality
Mad Chemist Chick
BBSRC/Douglas Kell
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
Chemical Crystallinity
ChemSpider Blog
Pharmagossip
Med-Chemist
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
Great Molecular Crapshoot
No Name No Slogan
Practical Fragments
SimBioSys
Culture of Chemistry
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Zusammen
My Chemical Journey
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
Curly Arrow
ChemCafe
Fetz the Chemist
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Life of a Lab Rat
Nobel Intent
SciTech Daily
Is This Thing On?
Science Blog
Eastern Blot
FuturePundit
Flags and Lollipops
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Terra Sigillata
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Living the Scientific Life
Humans in Science
Speculist
Science, Shrimp and Grits
Cosmic Variance
The Capsule
Zeroth Order Approximation
Science Library Blog
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« A Breath of Fresh Air from Fuji | Main | Tote That Barge, Lift That Bale »

June 3, 2008

Oops

Email This Entry

Posted by Derek

We recently encountered a problem that’s (unfortunately) a rather common one. An enzyme assay turned up an interesting hit compound, with some characteristics that we were hoping to see for leads against our target. A re-test showed that yes, the activity appeared to be real, which was interesting, since this hit was a welcome surprise from a class of compounds that we weren’t expecting much from.

It was a comparatively old compound in the files, and all we could find out was that it had been purchased rather than made in house. Looking around, it seemed that there were very few literature references to things of this type, and only one commercial source: the Sigma-Aldrich Library of Rare chemicals, known as SALOR. That, though, was a potential warning flag.

Those compounds come from an effort started by Aldrich’s Alfred Bader many years ago, who started trolling around various academic labs looking for unusual compounds that no one wanted to keep around any more. Over time the company has accumulated a horde of oddities that are often found nowhere else, but there are several catches. For one, these things are usually available only in small quantities, tens of milligrams for the most part. That’s plenty for the screening files, but you’re not going to make a bunch of analogs starting from what comes out of a SALOR vial. Another catch is that the compounds are sold, very explicitly, as is: the university sources tell Aldrich what’s on the label, so that’s what they sell you and caveat emptor all the way, dude.

So often as not, you get what we got, a nice-looking white powder which, on closer analysis, turned out to only have a vague relationship to the structure on its label. We knew that we were in trouble as soon as the first NMR came out: way too much stuff in one region, nowhere near enough in some others. Mass spec confirmed that this thing weighed more than twice as much as what it was supposed to. We’ve since pretty much nailed down what the stuff really is, and our interest in it has decreased as each of the veils has been removed from the real structure.

We’re correcting the data in our own screening files, of course. And yes, we’re going to tell the folks at Aldrich to change their label, too, assuming they have any of this stuff left. At least the next person will know what they’re getting. For once. But there are more of these things waiting out there – in every large compound collection, in every catalog, in every collection of data are mistakes. Watch for them.

Comments (4) + TrackBacks (0) | Category: Drug Assays | Life in the Drug Labs


COMMENTS

1. petros on June 3, 2008 8:22 AM writes...

Derek

It can happend with inhouse stuff too, albeit I'd guess less frequently now.

In the WDF a certian "tricylcic" showed up as a great hit but when more was required it proved impossible to make. But testing showed that the final step had never resulted in cyclization- someone either didn't run or had ignored the NMR!

Permalink to Comment

2. SP on June 3, 2008 8:41 AM writes...

We're changing out collection so that we only screen things that are >75% pure by in-house LCMS- anything else is purged from the screening deck. No more mystery mixes.

Permalink to Comment

3. Chris C on June 3, 2008 9:50 AM writes...

As a molecular biologist I can tell you that we are not immune to this problem. I cannot tell you how many plasmids, strains, and cell lines turn out not to be what I expected. I haven't had this problem in a commerically purchased product, which is probably the best reason to purchase a plasmid from a company rather than getting it from somebody. From now on I will sequence important parts of all my new plasmids and at the very least do a restriction digest. Laziness about these precautions is one of the leading causes of wasted time.

Permalink to Comment

4. Merkwurdigliebe on June 3, 2008 10:29 AM writes...

Caveat Emptor, indeed. Adding a compound to the library without verifying it's identity is rather like buying a house site-unseen.

I wonder where Aldrich found it.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
A GSK/Sirtris Wrap-Up
Hope Darn Well Springs Eternal
Bad News at Exelixis
Not Gonna Make That One
Merck/Schering-Plough People?
Friday Book Recommendation
Twelve and One Half Per Cent
Your Own Personal Bacteria